CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing carbon monoxide releasing molecules (CORMs) for treating rheumatoid arthritis. By delivering carbon monoxide in controlled amounts to inflamed tissues, the project aims to create effective therapies for chronic inflammatory diseases.
The project will focus on the pre-clinical development of carbon monoxide releasing molecules (CORMs) for the treatment of rheumatoid arthritis (RA).
Carbon monoxide (CO) has been shown, by several renowned laboratories around the world, to have a number of anti-inflammatory properties which turn it into an exceptionally promising compound against chronic inflammatory diseases such as RA.
In its gaseous form CO will hardly be applicable as a drug in a clinical setting.
One proponent SME, has c…
Alfama - Investigacao e Desenvolvimento de Produtos Farmaceuticos, Lda.
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Switzerland, Fribourg
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Italy, Venturina (Livorno)
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Italy, Catania
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
